Current issues in the economics of vaccination against dengue

Research output: Contribution to journalArticle

Abstract

Dengue is a major public health concern in tropical and subtropical areas of the world. The prospects for dengue prevention have recently improved with the results of efficacy trials of a tetravalent dengue vaccine. Although partially effective, once licensed, its introduction can be a public health priority in heavily affected countries because of the perceived public health importance of dengue. This review explores the most immediate economic considerations of introducing a new dengue vaccine and evaluates the published economic analyses of dengue vaccination. Findings indicate that the current economic evidence base is of limited utility to support country-level decisions on dengue vaccine introduction. There are a handful of published cost-effectiveness studies and no country-specific costing studies to project the full resource requirements of dengue vaccine introduction. Country-level analytical expertise in economic analyses, another gap identified, needs to be strengthened to facilitate evidence-based decision-making on dengue vaccine introduction in endemic countries.

Original languageEnglish (US)
Pages (from-to)519-528
Number of pages10
JournalExpert Review of Vaccines
Volume15
Issue number4
DOIs
StatePublished - Apr 2 2016

Fingerprint

Dengue Vaccines
Dengue
Vaccination
Economics
Public Health
Health Priorities
Cost-Benefit Analysis
Decision Making

Keywords

  • affordability
  • cost-effectiveness
  • dengue
  • Dengue vaccination
  • dengue vaccines
  • developing countries
  • economic evaluation
  • low- and middle-income countries
  • national immunization programs
  • sustainability

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Current issues in the economics of vaccination against dengue. / Tozan, Yesim.

In: Expert Review of Vaccines, Vol. 15, No. 4, 02.04.2016, p. 519-528.

Research output: Contribution to journalArticle

@article{b9b25175ebf14301b0b9b2110deddd91,
title = "Current issues in the economics of vaccination against dengue",
abstract = "Dengue is a major public health concern in tropical and subtropical areas of the world. The prospects for dengue prevention have recently improved with the results of efficacy trials of a tetravalent dengue vaccine. Although partially effective, once licensed, its introduction can be a public health priority in heavily affected countries because of the perceived public health importance of dengue. This review explores the most immediate economic considerations of introducing a new dengue vaccine and evaluates the published economic analyses of dengue vaccination. Findings indicate that the current economic evidence base is of limited utility to support country-level decisions on dengue vaccine introduction. There are a handful of published cost-effectiveness studies and no country-specific costing studies to project the full resource requirements of dengue vaccine introduction. Country-level analytical expertise in economic analyses, another gap identified, needs to be strengthened to facilitate evidence-based decision-making on dengue vaccine introduction in endemic countries.",
keywords = "affordability, cost-effectiveness, dengue, Dengue vaccination, dengue vaccines, developing countries, economic evaluation, low- and middle-income countries, national immunization programs, sustainability",
author = "Yesim Tozan",
year = "2016",
month = "4",
day = "2",
doi = "10.1586/14760584.2016.1129278",
language = "English (US)",
volume = "15",
pages = "519--528",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Current issues in the economics of vaccination against dengue

AU - Tozan, Yesim

PY - 2016/4/2

Y1 - 2016/4/2

N2 - Dengue is a major public health concern in tropical and subtropical areas of the world. The prospects for dengue prevention have recently improved with the results of efficacy trials of a tetravalent dengue vaccine. Although partially effective, once licensed, its introduction can be a public health priority in heavily affected countries because of the perceived public health importance of dengue. This review explores the most immediate economic considerations of introducing a new dengue vaccine and evaluates the published economic analyses of dengue vaccination. Findings indicate that the current economic evidence base is of limited utility to support country-level decisions on dengue vaccine introduction. There are a handful of published cost-effectiveness studies and no country-specific costing studies to project the full resource requirements of dengue vaccine introduction. Country-level analytical expertise in economic analyses, another gap identified, needs to be strengthened to facilitate evidence-based decision-making on dengue vaccine introduction in endemic countries.

AB - Dengue is a major public health concern in tropical and subtropical areas of the world. The prospects for dengue prevention have recently improved with the results of efficacy trials of a tetravalent dengue vaccine. Although partially effective, once licensed, its introduction can be a public health priority in heavily affected countries because of the perceived public health importance of dengue. This review explores the most immediate economic considerations of introducing a new dengue vaccine and evaluates the published economic analyses of dengue vaccination. Findings indicate that the current economic evidence base is of limited utility to support country-level decisions on dengue vaccine introduction. There are a handful of published cost-effectiveness studies and no country-specific costing studies to project the full resource requirements of dengue vaccine introduction. Country-level analytical expertise in economic analyses, another gap identified, needs to be strengthened to facilitate evidence-based decision-making on dengue vaccine introduction in endemic countries.

KW - affordability

KW - cost-effectiveness

KW - dengue

KW - Dengue vaccination

KW - dengue vaccines

KW - developing countries

KW - economic evaluation

KW - low- and middle-income countries

KW - national immunization programs

KW - sustainability

UR - http://www.scopus.com/inward/record.url?scp=84952836914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952836914&partnerID=8YFLogxK

U2 - 10.1586/14760584.2016.1129278

DO - 10.1586/14760584.2016.1129278

M3 - Article

C2 - 26642099

AN - SCOPUS:84952836914

VL - 15

SP - 519

EP - 528

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 4

ER -